STONY BROOK, New York and
MUMBAI, India, February 26, 2018 /PRNewswire/ --
Collaboration to help thwart
counterfeits with molecular tagging of capsules
Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the
"Company"), and ACG have signed a memorandum of understanding (MoU)
that will allow ACG to utilize Applied DNA's proven SigNature®
molecular tagging and authentication technologies to develop
molecularly tagged empty hard-shell capsules for offering to ACG's
customers to enhance product traceability and authentication. The
MoU is expected to be followed by a definitive agreement.
(Logo:
https://mma.prnewswire.com/media/640402/ACG_Logo.jpg )
The empty capsules market witnessed healthy
growth during the last decade and is expected to grow at a CAGR of
7.2% between 2016 and 2021 to reach USD 2.13
billion by 2021.
The development of molecularly tagged empty hard-shell capsules
will allow ACG's customers to enhance every distribution channel's
integrity. It will also provide pharmaceutical companies with
increased and assured capabilities when investigating suspected
counterfeit medicines and help enhance patient and regulator
confidence in pharmaceutical companies and their supply chains.
Applied DNA's SigNature technology allows the embedding of a
bespoke molecular tag into one or more capsule component materials.
Each customer's molecular tag can be formulated to specifically
adhere tenaciously to a wide variety of substrates and is optimized
to allow for authentication at any point in the pharmaceutical
supply chain.
On the association between ACG and Applied DNA, Mr. Selwyn Noronha, CEO, ACG
Capsules said, "With the increasing threat of counterfeits
in the pharmaceutical supply chain and regulations mandating
companies to deploy strategies such as serialization and to have
greater awareness, there is a need for innovative and effective
solutions for product authentication, track and trace and supply
chain integrity. We strongly believe that our association with
Applied DNA is a step towards nipping the counterfeiting problem
that is grappling the industry today. With the introduction of
stricter regulatory norms and measures across the globe, the
pressure lies increasingly in improving existing supply chain
safeguards. The association will equip pharmaceutical companies
with greater capabilities to thwart the threat of counterfeits by
providing amplified traceability solution across the supply
chain."
Elaborating on the association, Dr. James Hayward, President and CEO of Applied DNA
said, "We are proud to announce the signing of the MoU and are
excited by ACG's development of on-dose authentication for
hard-shell capsules powered by the Company's SigNature molecular
tagging and authentication technologies. The ability to
forensically test a capsule in the field and quickly prove its
provenance is a powerful tool for all nodes of the pharmaceutical
supply chain and will ensure a more secure and traceable global
pharmaceutical supply chain."
Visit http://www.acg-world.com for more
information. Follow us on Twitter
and LinkedIn.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and DNA mass production for
diagnostics and therapeutics.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion. The proprietary DNA-based
"CertainT™" platform can be used to identify, tag, test, and track
products, to help assure authenticity, origin, traceability,
sustainability and quality of products.
SigNature® DNA describes the core technology ingredient that is
at the heart of a family of uncopiable, security and authentication
solutions such as SigNature®T and fiberTyping®, targeted towards
textiles and apparel, BackTrac® and DNAnet®, for anti-theft and
loss prevention, and digitalDNA®, providing powerful
track-and-trace. All provide a forensic chain of evidence, and can
be used to prosecute perpetrators. Applied DNA Sciences is also
engaged in the large-scale production of specific DNA sequences
using the polymerase chain reaction.
Visit adnas.com for more information. Follow us
on Twitter and LinkedIn. Join
our mailing list.
About ACG
The ACG group is the only supplier in the world offering
integrated manufacturing solutions for the pharmaceutical industry.
The company's diverse product range of Capsules, Films & Foils,
Engineering and Inspection systems don't just meet, but exceeds the
demands of international regulatory requirements. ACG is committed
to just one goal: to offer everything needed for efficient capsule
and tablet manufacturing.
ACG has over 5 decades of experience and is present in over 100
countries, with over 4,500 employees around the world. Our
customer-centric approach has won us many loyal, satisfied
customers and partners by nurturing relationships with dignity and
transparency.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA's future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to our lack of significant revenues, limited
financial resources, limited market acceptance, history of net
losses, market competition and various other factors detailed from
time to time in Applied DNA's SEC reports and filings, including
our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly
report on Form 10-Q filed on February 8,
2018, which are available at http://www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.
For further information, please contact:
Cheryl Schneider
212-825-3210
cschneider@dgicomm.com
Bob Miglani
631-240-8800
bob.miglani@adnas.com
Tanya Grover
tanya.grover@acg-world.com
Web: http://www.adnas.com
Twitter: @APDN